ES2189059T3 - Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion. - Google Patents

Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.

Info

Publication number
ES2189059T3
ES2189059T3 ES98117718T ES98117718T ES2189059T3 ES 2189059 T3 ES2189059 T3 ES 2189059T3 ES 98117718 T ES98117718 T ES 98117718T ES 98117718 T ES98117718 T ES 98117718T ES 2189059 T3 ES2189059 T3 ES 2189059T3
Authority
ES
Spain
Prior art keywords
talidomide
procedure
preparation
parenteral administration
new prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98117718T
Other languages
English (en)
Inventor
Sven Bjorkman
Peter Hoglund
Tommy Eriksson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7844650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2189059(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2189059T3 publication Critical patent/ES2189059T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

SE DESCRIBE UNA SOLUCION ACUOSA DE TALIDOMIDA, QUE ES APROPIADA PARA SU INYECCION PARENTERAL, EN PARTICULAR INTRAVENOSA DE LA TALIDOMIDA PARA LA TERAPIA DE ENFERMEDADES INMUNOLOGICAS, ASI COMO UN PROCEDIMIENTO PARA LA PREPARACION DE LA CORRESPONDIENTE SOLUCION DE TALIDOMIDA.
ES98117718T 1997-10-06 1998-09-18 Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion. Expired - Lifetime ES2189059T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19743968A DE19743968C2 (de) 1997-10-06 1997-10-06 Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Publications (1)

Publication Number Publication Date
ES2189059T3 true ES2189059T3 (es) 2003-07-01

Family

ID=7844650

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98117718T Expired - Lifetime ES2189059T3 (es) 1997-10-06 1998-09-18 Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.

Country Status (13)

Country Link
US (1) US6124322A (es)
EP (1) EP0908176B1 (es)
JP (1) JPH11189534A (es)
AT (1) ATE229323T1 (es)
AU (1) AU732634B2 (es)
CA (1) CA2248838A1 (es)
DE (2) DE19743968C2 (es)
DK (1) DK0908176T3 (es)
ES (1) ES2189059T3 (es)
HU (1) HUP9802206A1 (es)
NZ (1) NZ331563A (es)
PT (1) PT908176E (es)
SI (1) SI0908176T1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
PT1040838E (pt) * 1999-03-31 2003-08-29 Gruenenthal Gmbh Solucao aquosa estavel de 3-(1-oxo-1,3-di-hidro-isoindol-2-il)piperidino-2,6-diona
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
WO2000072836A2 (en) * 1999-05-27 2000-12-07 The Rockefeller University Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
GB2371767A (en) * 2001-02-02 2002-08-07 Labman Automation Ltd Dissolving materials by application of agitation and ultrasound
EP1389203B8 (en) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
CA2808646C (en) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
JP2022529720A (ja) * 2019-04-22 2022-06-23 スタートン セラピューティクス インコーポレイテッド レナリドミドまたは他の免疫調節剤の持続投与
EP4251131A1 (en) 2021-01-08 2023-10-04 Starton Therapeutics, Inc. Stable solutions of immunomodulatory imide compounds for parenteral use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
AU661299B2 (en) * 1991-04-17 1995-07-20 Grunenthal Gmbh New thalidomide derivatives, method of manufacture and use thereof in medicaments
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Also Published As

Publication number Publication date
DE19743968A1 (de) 1999-04-15
PT908176E (pt) 2003-04-30
CA2248838A1 (en) 1999-04-06
US6124322A (en) 2000-09-26
DE19743968C2 (de) 2002-07-11
ATE229323T1 (de) 2002-12-15
DK0908176T3 (da) 2003-01-06
NZ331563A (en) 1999-01-28
HUP9802206A1 (hu) 2000-12-28
HK1018591A1 (en) 1999-12-30
HU9802206D0 (en) 1998-11-30
JPH11189534A (ja) 1999-07-13
AU8792598A (en) 1999-04-22
SI0908176T1 (en) 2003-04-30
EP0908176A1 (de) 1999-04-14
EP0908176B1 (de) 2002-12-11
DE59806612D1 (de) 2003-01-23
AU732634B2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
ES2189059T3 (es) Nuevo preparado para la administracion parenteral de la talidomida y procedimiento para su preparacion.
PY950041A (es) Compuesto de 1- fenil 3-dimetilamino- propano a procedimientos para su preparacion y a la aplicacion de estas sustancias en farmacologia
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
EA199800946A1 (ru) Концентрированный препарат антител
DE69938923D1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
ES2188783T3 (es) Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
MY124695A (en) Novel composition and use.
CO5540369A2 (es) Perfil farmococinetico mejorado de sustancias hidrofobas
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
GB9818916D0 (en) Use
CY2562B1 (en) Pharmaceutical injectable solution of paracetamol and combinations of paracetamol with other active substances
AU5547501A (en) Method of reducing side effects of chemotherapy in cancer patients
ES2193216T3 (es) Dipeptidil peptidasa iv y su procedimiento de preparacion.
EA199900633A1 (ru) Способы терапевтического введения анти-cd40l соединений
PT1007055E (pt) Utilizacao de amifostina
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
ES2148493T3 (es) Nuevos compuestos con efecto analgesico y anestesico local.
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.